MIRA Pharmaceuticals, Inc.
MIRANASDAQHealthcare● Active
$1.00
+$0.00(+0.00%)
Market Cap$42022087
P/E Ratio—
52W High$2.45
52W Low$0.9
MIRA Pharmaceuticals, Inc. (MIRA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MIRA · earnings · updated Jun 10, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.03
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
MIRA reports quarterly as a NASDAQ-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | May 14, 2026 | — | -$0.03 | — | — | — | — |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$0.04 | -$0.15 | -275.0% | — | — | — |
| — Q4 FY2025 | Nov 13, 2025 | -$1.18 | -$1.18 | +0.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.11 | -$0.09 | +18.2% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.15 | -$0.11 | +26.7% | — | — | — |
| ▲ Q1 FY2025 | Mar 28, 2025 | -$0.29 | -$0.15 | +48.3% | $0.01B | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.18 | -$0.14 | +22.2% | — | — | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$0.15
EPS Est.
-$0.04
EPS Surpr.
-275.0%
Revenue
—
Q4 FY2025
Nov 13, 2025
EPS Actual
-$1.18
EPS Est.
-$1.18
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.11
EPS Surpr.
+18.2%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.15
EPS Surpr.
+26.7%
Revenue
—
Q1 FY2025
Mar 28, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.29
EPS Surpr.
+48.3%
Revenue
$0.01B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.14
EPS Est.
-$0.18
EPS Surpr.
+22.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2025 | $-1.18 | $-1.18 | $-1.18 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 14, 2026 | — | $0.97 | $0.98 | +0.42% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -275.0% | $0.96 | $1.07 | +11.08% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +0.0% | $1.43 | $1.34 | -6.29% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +18.2% | $1.49 | $1.47 | -1.34% |
| ▲ Q2 FY2025 | May 14, 2025 | +26.7% | $1.18 | $1.33 | +12.71% |
| ▲ Q1 FY2025 | Mar 28, 2025 | +48.3% | $1.10 | $1.06 | -3.64% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +22.2% | $1.71 | $1.60 | -6.43% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -10.0% | $2.11 | $2.05 | -2.84% |
Q2 FY2026+0.42%
Report Date
May 14, 2026
EPS Beat/Miss
—
Price Before
$0.97
Price After
$0.98
Q1 FY2026+11.08%
Report Date
Mar 31, 2026
EPS Beat/Miss
-275.0%
Price Before
$0.96
Price After
$1.07
Q4 FY2025-6.29%
Report Date
Nov 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.43
Price After
$1.34
Q3 FY2025-1.34%
Report Date
Aug 14, 2025
EPS Beat/Miss
+18.2%
Price Before
$1.49
Price After
$1.47
Q2 FY2025+12.71%
Report Date
May 14, 2025
EPS Beat/Miss
+26.7%
Price Before
$1.18
Price After
$1.33
Q1 FY2025-3.64%
Report Date
Mar 28, 2025
EPS Beat/Miss
+48.3%
Price Before
$1.10
Price After
$1.06
Q4 FY2024-6.43%
Report Date
Nov 12, 2024
EPS Beat/Miss
+22.2%
Price Before
$1.71
Price After
$1.60
Q3 FY2024-2.84%
Report Date
Aug 13, 2024
EPS Beat/Miss
-10.0%
Price Before
$2.11
Price After
$2.05
Avg Beat Reaction-1.00%
Avg Miss Reaction+4.12%
Beat Rate5 / 8 quarters
Largest Move+12.71% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MIRA ends December
MIRA Pharmaceuticals, Inc. (MIRA) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.03 (in line with the analyst consensus of —).
Each quarter, investors track MIRA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MIRA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MIRA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MIRA earnings · 4 questionsMIRA Pharmaceuticals, Inc.'s next earnings report is expected around TBD. MIRA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MIRA historically reports after market close (AMC).
MIRA earnings datewhen is MIRA earningsMIRA next earnings datewhen does MIRA report earningsMIRA earnings calendar
▸ Source: FMP · MIRA Pharmaceuticals, Inc. SEC filings · US GAAP · MIRA Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026